Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016;9(2):65-90.
doi: 10.1159/000443344. Epub 2016 Apr 8.

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)

EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

European Association for the Study of the Liver (EASL) et al. Obes Facts. 2016.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Diagnostic flow-chart to assess and monitor disease severity in the presence of suspected NAFLD and metabolic risk factors. aSteatosis biomarkers: Fatty Liver Index, SteatoTest, NAFLD Fat score (see tables). bLiver tests: ALT AST, γ-glutamyltransferase (GGT). cAny increase in ALT, AST or γ-glutamyltransferase (GGT). dSerum fibrosis markers: NAFLD Fibrosis Score, FIB-4, Commercial tests (FibroTest, FibroMeter, ELF). eLow risk: indicative of no/mild fibrosis; medium/high risk: indicative of significant fibrosis or cirrhosis (see tables).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–384. - PubMed
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926. - PMC - PubMed
    1. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117. - PubMed
    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. - PubMed
    1. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine. 2012;91:319–327. - PubMed